Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lemann Index

被引:25
作者
Bodini, Giorgia [1 ]
Giannini, Edoardo G. [1 ]
De Maria, Costanza [1 ]
Dulbecco, Pietro [1 ]
Furnari, Manuele [1 ]
Marabotto, Elisa [1 ]
Savarino, Vincenzo [1 ]
Savarino, Edoardo [2 ]
机构
[1] Univ Genoa, Dept Internal Med, Gastroenterol Unit, Genoa, Italy
[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Gastroenterolgy Unit, Padua, Italy
关键词
Adalimumab; Follow-up; Inflammatory bowel disease; Infliximab; Treatment; POSTOPERATIVE RECURRENCE; POSTSURGICAL RECURRENCE; RHEUMATOID-ARTHRITIS; ADALIMUMAB; VALIDATION; VALUES;
D O I
10.1016/j.dld.2016.10.014
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims: The Lemann Index (LI) was developed to assess the cumulative structural damage of the intestinal tract in patients with Crohn's Disease (CD) independently of clinical and biochemical activity. Recently, the goal of CD focused on obtaining mucosal healing and deep remission rather than simple symptom control. These new therapeutic aims emphasize the need to prevent progression of bowel damage. In this study we aimed to evaluate the influence of different treatments on structural damage progression, assessed by means of LI in a series of CD patients consistently treated with various drugs. Methods: The LI was calculated at inclusion and at the end of follow-up in 104 CD patients subdivided according to treatments received: biological drugs (n = 40, 38.4%), azathioprine (n = 19, 18.3%), and mesalazine (n = 45, 43.3%). Results: The median follow-up was 29 months, with no difference among groups. During follow-up, the median LI was stable in the biological group [from 6.3 (range, 0.6-37.3) to 6.4 (range, 0.6-37.6), P = 0.543], whereas it significantly increased from 4.1 (range, 0.6-30) to 8.3 (range, 0.6-31.8) in the azathioprine group (P = 0.0006), and from 2.4 (range, 0.6-25.8) to 4.1 (range, 0.6-28.8) in the mesalazine group (P < 0.0001). Also during follow-up the LI increased significantly (P = 0.004) in the azathioprine (68.4%) and mesalazine (60.0%) groups as compared with the biological therapy group (30.0%). Conclusions: In CD patients the LI tends to increase over time, although the use of biological drugs rather than azathioprine or mesalazine seems to be able to reduce the progressive bowel damage. (C) 2016 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 28 条
[1]  
BEST WR, 1979, GASTROENTEROLOGY, V77, P843
[2]  
BEST WR, 1976, GASTROENTEROLOGY, V70, P439
[3]   Low serum trough levels are associated with post-surgical recurrence in Crohn's disease patients undergoing prophylaxis with adalimumab [J].
Bodini, Giorgia ;
Savarino, Vincenzo ;
Peyrin-Biroulet, Laurent ;
de Cassan, Chiara ;
Dulbecco, Pietro ;
Baldissarro, Isabella ;
Fazio, Valentina ;
Giambruno, Elisa ;
Savarino, Edoardo .
DIGESTIVE AND LIVER DISEASE, 2014, 46 (11) :1043-1046
[4]  
Boini S, 2001, ANN RHEUM DIS, V60, P817
[5]   Review article: the natural history of postoperative Crohn's disease recurrence [J].
Buisson, A. ;
Chevaux, J. -B. ;
Allen, P. B. ;
Bommelaer, G. ;
Peyrin-Biroulet, L. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (06) :625-633
[6]   Long-term evolution of disease behavior of Crohn's disease [J].
Cosnes, J ;
Cattan, S ;
Blain, A ;
Beaugerie, L ;
Carbonnel, F ;
Parc, R ;
Gendre, JP .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (04) :244-250
[7]   Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD [J].
Daperno, M ;
D'Haens, G ;
Van Assche, G ;
Baert, F ;
Bulois, P ;
Maunoury, V ;
Sostegni, R ;
Rocca, R ;
Pera, A ;
Gevers, A ;
Mary, JY ;
Colombel, JF ;
Rutgeerts, P .
GASTROINTESTINAL ENDOSCOPY, 2004, 60 (04) :505-512
[8]   Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: An expert consensus report [J].
Feagan, Brian G. ;
Lemann, Marc ;
Befrits, Ragnar ;
Connell, William ;
D'Haens, Geert ;
Ghosh, Subrata ;
Michetti, Pierre ;
Ochsenkuehn, Thomas ;
Panaccione, Remo ;
Schreiber, Stefan ;
Silverberg, Mark ;
Sorrentino, Dario ;
van der Woude, C. Janneke ;
Vermeire, Severine ;
Rutgeerts, Paul .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (01) :152-160
[9]   Bowel Damage as Assessed by the Lemann Index is Reversible on Anti-TNF Therapy for Crohn's Disease [J].
Fiorino, Gionata ;
Bonifacio, Cristiana ;
Allocca, Mariangela ;
Repici, Alessandro ;
Balzarini, Luca ;
Alberto, Malesci A. ;
Peyrin-Biroulet, Laurent ;
Danese, Silvio .
JOURNAL OF CROHNS & COLITIS, 2015, 9 (08) :633-639
[10]   Risk of Surgery for Inflammatory Bowel Diseases Has Decreased Over Time: A Systematic Review and Meta-analysis of Population-Based Studies [J].
Frolkis, Alexandra D. ;
Dykeman, Jonathan ;
Negron, Maria E. ;
deBruyn, Jennifer ;
Jette, Nathalie ;
Fiest, Kirsten M. ;
Frolkis, Talia ;
Barkema, Herman W. ;
Rioux, Kevin P. ;
Panaccione, Remo ;
Ghosh, Subrata ;
Wiebe, Samuel ;
Kaplan, Gilaad G. .
GASTROENTEROLOGY, 2013, 145 (05) :996-1006